338 related articles for article (PubMed ID: 14581407)
1. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape.
Hu L; Sealey JE; Chen R; Zhou Y; Merali C; Shi Y; Laragh JH; Catanzaro DF
Am J Hypertens; 2004 May; 17(5 Pt 1):395-403. PubMed ID: 15110897
[TBL] [Abstract][Full Text] [Related]
4. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition.
Kaikita K; Schoenhard JA; Painter CA; Ripley RT; Brown NJ; Fogo AB; Vaughan DE
J Mol Cell Cardiol; 2002 Jun; 34(6):617-27. PubMed ID: 12054849
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis.
Katoh M; Egashira K; Mitsui T; Chishima S; Takeshita A; Narita H
J Mol Cell Cardiol; 2000 Jan; 32(1):73-83. PubMed ID: 10652192
[TBL] [Abstract][Full Text] [Related]
6. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
7. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
Knier B; Cordasic N; Klanke B; Heusinger-Ribeiro J; Daniel C; Veelken R; Hartner A; Hilgers KF
J Hypertens; 2011 Aug; 29(8):1602-12. PubMed ID: 21610512
[TBL] [Abstract][Full Text] [Related]
8. Cooperative Role of Mineralocorticoid Receptor and Caveolin-1 in Regulating the Vascular Response to Low Nitric Oxide-High Angiotensin II-Induced Cardiovascular Injury.
Pojoga LH; Yao TM; Opsasnick LA; Siddiqui WT; Reslan OM; Adler GK; Williams GH; Khalil RA
J Pharmacol Exp Ther; 2015 Oct; 355(1):32-47. PubMed ID: 26183312
[TBL] [Abstract][Full Text] [Related]
9. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.
Martinez DV; Rocha R; Matsumura M; Oestreicher E; Ochoa-Maya M; Roubsanthisuk W; Williams GH; Adler GK
Hypertension; 2002 Feb; 39(2 Pt 2):614-8. PubMed ID: 11882618
[TBL] [Abstract][Full Text] [Related]
10. Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling.
Hou Y; Okada K; Okamoto C; Ueshima S; Matsuo O
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1257-62. PubMed ID: 18436805
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells.
Mazak I; Fiebeler A; Muller DN; Park JK; Shagdarsuren E; Lindschau C; Dechend R; Viedt C; Pilz B; Haller H; Luft FC
Circulation; 2004 Jun; 109(22):2792-800. PubMed ID: 15159288
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes.
Chun TY; Pratt JH
Mol Cell Endocrinol; 2005 Jul; 239(1-2):55-61. PubMed ID: 15921847
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Rocha R; Stier CT; Kifor I; Ochoa-Maya MR; Rennke HG; Williams GH; Adler GK
Endocrinology; 2000 Oct; 141(10):3871-8. PubMed ID: 11014244
[TBL] [Abstract][Full Text] [Related]
15. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
[TBL] [Abstract][Full Text] [Related]
16. [Effect of aldosterone on the expression of plasminogen activator inhibitor-1 in renal mesangial cells: experiment with rat renal mesangial cells].
Yuan J; Jia RH; Bao Y
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2439-42. PubMed ID: 18036328
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
19. Systemic Aldosterone, But Not Angiotensin II, Plays a Pivotal Role in the Pathogenesis of Renal Injury in Chronic Nitric Oxide-Deficient Male Rats.
Suehiro T; Tsuruya K; Ikeda H; Toyonaga J; Yamada S; Noguchi H; Tokumoto M; Kitazono T
Endocrinology; 2015 Jul; 156(7):2657-66. PubMed ID: 25872005
[TBL] [Abstract][Full Text] [Related]
20. Circadian expression of plasminogen activator inhibitor-1 in angiotensin II type 1a receptor knockout mice.
Tsujino T; Naito Y; Kawasaki D; Okuda S; Sakoda T; Fujioka Y; Sugaya T; Ohyanagi M
Clin Exp Hypertens; 2005; 27(2-3):159-68. PubMed ID: 15835378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
